Thus, targeting ATR–CHK1 not only exploits intrinsic vulnerabilities in gastric cancer cells but also transforms the tumor-immune interface, offering a promising strategy for overcoming therapeutic resistance and immunotherapy insensitivity in gastric cancer [119,124,125]. This evidence concerns the gene CHEK1 and neoplasm.